Lorem ipsum dolor sit amet, consectetur adipiscing elit. Pellentesque sagittis tincidunt leo, vel condimentum ipsum fringilla tincidunt. Curabitur vitae congue nisl. Etiam eros ipsum, rutrum sit amet luctus sit amet, tempor sit amet odio. Aenean ultricies et nisi a finibus. Donec ullamcorper maximus ex, at eleifend nisl tincidunt et. Curabitur suscipit tellus eu sapien congue, sed euismod enim vulputate. Aliquam eget felis sit amet erat congue pharetra. Mauris hendrerit fermentum ex eu finibus. Cras ornare neque vel enim convallis mattis. Nulla luctus lorem rutrum diam dictum suscipit. Maecenas scelerisque mi laoreet magna ornare dapibus.

Mauris pellentesque massa semper massa semper tempus. Nulla sapien turpis, feugiat sit amet imperdiet at, gravida vitae eros. Integer efficitur pretium tincidunt. In mattis egestas dolor fringilla tincidunt. Phasellus eget lacus quis massa pretium eleifend. Cras quis luctus leo, sed laoreet odio. Sed eu tempor sapien, sed rhoncus mi. Sed interdum varius quam, efficitur viverra nunc maximus ac. Suspendisse eget lacus vel lorem bibendum tempus. Donec mattis posuere porttitor. Donec libero nisi, euismod eu auctor eu, mollis id tortor.

• Today's heart transplant procedures and the evolution of the surgery 
• Complications/successes in heart transplantation 
• The future for heart transplants 

• The association of diabetes mellitus and cardiovascular disease 
• Hyperlipidaemia, cholesterolemia and cardiovascular complications 
• Different anti-lipid and anti-diabetes and the link to CVD 

• A better understanding of individual heart disease/failure  
• Device therapy in treatment of the heart  
• Developments in treatment methods – what's being used across the EU 

Prescribing information:

Prescribing Information Forxiga (Dapagliflozin) Great Britain:  https://medicines.astrazeneca.co.uk/content/dam/multibrand/uk/en/prescribinginformation/Forxiga-GB-PI.pdf

Prescribing Information Forxiga (Dapagliflozin) Northern Ireland: https://medicines.astrazeneca.co.uk/content/dam/multibrand/uk/en/prescribinginformation/Forxiga-NI-PI.pdf

Adverse Events:

Adverse events should be reported.  Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.  

Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com or by calling 0800 783 0033

If you have any questions, comments or queries, please email:  https://contactazmedical.astrazeneca.com/

• Development of increasingly potent cancer therapies, at the cost of cardiovascular toxicity 
• Host institutes for cardio-oncology services, the potential and progress 
• Understanding the CV health problem in cancer survivors and how services have arisen 

• Risk management for patients: history, habits and physical attributes 
• Managing heart disease through medical treatment and lifestyle management  
• Individualising preventative programs for patients 

• Procedures, technological developments and the conceptual trajectory 

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Pellentesque sagittis tincidunt leo, vel condimentum ipsum fringilla tincidunt. Curabitur vitae congue nisl. Etiam eros ipsum, rutrum sit amet luctus sit amet, tempor sit amet odio. Aenean ultricies et nisi a finibus. Donec ullamcorper maximus ex, at eleifend nisl tincidunt et. Curabitur suscipit tellus eu sapien congue, sed euismod enim vulputate. Aliquam eget felis sit amet erat congue pharetra. Mauris hendrerit fermentum ex eu finibus. Cras ornare neque vel enim convallis mattis. Nulla luctus lorem rutrum diam dictum suscipit. Maecenas scelerisque mi laoreet magna ornare dapibus.

Mauris pellentesque massa semper massa semper tempus. Nulla sapien turpis, feugiat sit amet imperdiet at, gravida vitae eros. Integer efficitur pretium tincidunt. In mattis egestas dolor fringilla tincidunt. Phasellus eget lacus quis massa pretium eleifend. Cras quis luctus leo, sed laoreet odio. Sed eu tempor sapien, sed rhoncus mi. Sed interdum varius quam, efficitur viverra nunc maximus ac. Suspendisse eget lacus vel lorem bibendum tempus. Donec mattis posuere porttitor. Donec libero nisi, euismod eu auctor eu, mollis id tortor.